



A general method for the asymmetric synthesis of both enantiomers of 1-substituted 1,2,3,4-tetrahydro- β -carbolines employing pyroglutamic acid derivatives as chiral auxiliaries

Takashi Itoh, Michiko Miyazaki, Sachiko Ikeda, Kazuhiro Nagata, Masashi Yokoya, Yuji Matsuya, Yasuko Enomoto and Akio Ohsawa*

School of Pharmaceutical Sciences, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan

Received 17 February 2003; accepted 14 March 2003

Abstract—9-(*S*)-Pyroglutaminy- β -carbolines were allowed to react with a nucleophile (allyltributyltin or a silyl enol ether) in the presence of 2,2,2-trichloroethyl chloroformate to give 1,2-addition products in good yields and high diastereoselectivity. The chiral auxiliary at *N*-9 was readily removed by a mild hydrolysis. The same chiral source afforded both enantiomers by simply altering a protecting group of the amide nitrogen. That is, (*S*)-pyroglutaminy groups which had an *N*-alkyl group afforded the (*S*) isomer, whereas the ones having an *N*-acyl group produced the (*R*) isomer of the addition products. © 2003 Elsevier Science Ltd. All rights reserved.

1. Introduction

β -Carboline (**1**) is a common nucleus of various indole alkaloids, and many of these have a chiral center at its C-1 position.¹ Thus, there have been several studies concerning the synthesis of chiral 1-substituted 1,2,3,4-tetrahydro- β -carboline derivatives using Pictet–Spengler reaction,² nucleophilic addition,³ electrophilic substitution,⁴ and reduction.⁵ We have recently developed the asymmetric addition of allyltin reagents to a β -carboline derivative which has an (*S*)-proline-derived chiral auxiliary at *N*-9 position.⁶ In addition, it was found that both enantiomers of a 1-allyl-1,2-dihydro- β -carboline derivative were obtained using allyltributyltin or tetraallyltin as a nucleophile in the presence of the same chiral auxiliary. The results indicate that the stereoselectivity of the allylation is not governed only by steric bias originated from the chiral auxiliary, and there might be some electrostatic interaction between the substrate and the nucleophiles. In fact, this peculiar stereoselectivity was not observed in the cases of other nucleophiles such as silyl enol ethers.

In order to develop a more general asymmetric addition, we have investigated other chiral auxiliaries than the proline derivatives and found that the one derived from (*S*)-pyroglutamic acid afforded good stereoselectivity using both allyltin and silyl enol ethers as nucleophiles. Moreover,

it was revealed that the *N*-alkyl- and *N*-acylpyroglutamic acids afforded opposite enantiomers by the attack of the same nucleophiles. This paper describes these results.⁷

2. Results and discussion


At first, we tried reactions using standard amino acids such as alanine, valine, or phenylalanine as a chiral auxiliary, and they were found not to install at *N*-9 position of **1** in good yields.⁸ Thus, we chose (*S*)-pyroglutamic acid as a candidate for a new chiral auxiliary, because it has a similar, but more rigid conformation with compared to proline due to carbonyl group in the pyrrolidine ring. Although pyroglutamic acid has been used for versatile building blocks for asymmetric synthesis,⁹ there are few examples using its derivatives as chiral auxiliaries.¹⁰ An *N*-protection step and succeeding addition to β -carboline proceeded without an event. Thus, *t*-butyl (*S*)-pyroglutamate (**2**) reacted with various *N*-protecting reagents in the presence of sodium hydride to give the derivatives **3**, which were transformed to the corresponding carboxylic acid **4** (Scheme 1 and Table 1).

The compound **4** thus obtained readily reacted with β -carboline by the use of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI) to give 9-acyl- β -carbolines **5** (Scheme 2 and Table 2). Therefore, the substrates **5** for asymmetric addition were prepared in good yields via three steps.

Firstly, asymmetric addition reaction was carried out using

Keywords: β -carboline; (*S*)-pyroglutamic acid; chiral auxiliary; asymmetric addition; allyltributyltin; silyl enol ether; indole alkaloid.

* Corresponding author. Tel.: +81-3-3784-8183; fax: +81-3-3784-5982; e-mail: ohsawa@pharm.showa-u.ac.jp




Scheme 1.

Table 1. Synthesis of the chiral auxiliary 4 from *t*-butyl (*S*)-pyroglutamate

| Entry | Compound | R | Temperature | Time 1 (h) | Yield of 3 (%) | Time 2 (h) | Yield of 4 (%) |
|-------|----------|---------------------------------|------------------|------------|----------------|-----------------|----------------|
| 1 | a | Me | Room temperature | 1 | 94 | 4 | 71 |
| 2 | b | PhCH ₂ | Reflux | 1 | 81 | 7 | 91 |
| 3 | c | 1-Naphthylmethyl | Reflux | 4 | 83 | 7 | 87 |
| 4 | d | 2-Naphthylmethyl | Reflux | 1 | 83 | 7 | 97 |
| 5 | e | 9-Anthracenylmethyl | Reflux | 10 | 75 | 22 ^a | 94 |
| 6 | f | MeCO | Reflux | 4.5 | 75 | 24 | 73 |
| 7 | g | PhCO | Room temperature | 24 | 74 | 24 | 90 |
| 8 | h | 9-Anthracenyl-CO | Reflux | 9 | 83 | 25 | 85 |
| 9 | i | <i>p</i> -NO ₂ -PhCO | Room temperature | 17 | 69 | 43 | 91 |
| 10 | j | PhSO ₂ | Room temperature | 1 | 69 | 15 | 76 |

^a 10 equiv. of TFA was used for the deprotection.



Scheme 2.

Table 2. Synthesis of 9-(pyroglutamyl)-β-carbolines (5)

| Entry | Compound | R | Time (h) | Yield of 5 (%) |
|-------|----------|---------------------------------|----------|----------------|
| 1 | a | Me | 3 | 86 |
| 2 | b | PhCH ₂ | 2 | 71 |
| 3 | c | 1-Naphthylmethyl | 1.5 | 77 |
| 4 | d | 2-Naphthylmethyl | 1.5 | 88 |
| 5 | e | 9-Anthracenylmethyl | 4 | 95 |
| 6 | f | MeCO | 24 | 71 |
| 7 | g | PhCO | 20 | 99 |
| 8 | h | 9-Anthracenyl-CO | 6 | 73 |
| 9 | i | <i>p</i> -NO ₂ -PhCO | 24 | 74 |
| 10 | j | PhSO ₂ | 2 | 91 |

allyltributyltin as a nucleophile (Scheme 3 and Table 3). In the event, the compound 5 was allowed to react with allyltributyltin and 2,2,2-trichloroethyl chloroformate to give a 1,2-dihydro adduct 6, which was subsequently hydrolyzed to 7 in a quantitative yield. The chiral auxiliary was completely recovered under mild hydrolytic conditions. The absolute configuration of the product 7 was determined according to the method reported earlier.⁶


As shown in Table 3, the chiral auxiliaries which have an alkyl *N*-protecting group afforded the *S* isomer of the product, while the use of the auxiliaries having an acyl *N*-protecting group resulted in the formation of the *R* isomer. Thus, it was revealed that both enantiomers were obtained in good to high chemical and optical yields by the simple change of *N*-protecting groups of the auxiliary.

In the cases of entries 1–5, the steric hindrance of the *N*-protecting group played an important role in the induction of the stereoselectivity, that is, the ee of the *S* isomer was increased with the bulkiness of the protecting groups. In the cases of *N*-acyl groups, however, the bulkiness seldom affected the selectivity, and only the chemical yields were lowered (entries 6–10).

Secondly, silyl enol ethers were used as nucleophiles,¹¹ and the results are summarized in Table 4 (Scheme 4).

In the previous system using a (*S*)-proline derivative as the auxiliary, silyl enol ethers added to the substrate only in low stereoselectivity.¹² In the present system, however, the reaction proceeded in a highly diastereoselective manner to give the dihydro adducts 8a–e in good yields after a mild hydrolysis. The change of the stereoselectivity was also observed in the cases of entries 6–8, and the same configurations (see below) as in the cases of Table 3 were obtained according to the used chiral auxiliaries. Thus, a general method for the synthesis of both enantiomers of 1-substituted 1,2,3,4-tetrahydro-β-carboline was accomplished using (*S*)-pyroglutamic acid as a chiral auxiliary.

For the determination of the configuration of the product in the reaction of silyl enol ethers, the adduct 8d (entry 4 of Table 4) was transformed to a tetrahydro derivative 10 according to the process mentioned in Scheme 5. The dihydro adduct was reduced with triethylsilane to give the corresponding tetrahydro derivative 9, which was further reduced with zinc–acetic acid, and succeeding esterification




Scheme 3.

Table 3. Asymmetric addition reaction of allyltributyltin with β -carboline which has a chiral auxiliary derived from pyroglutamic acid at *N*-9


| Entry | Compound | R | Yield of 6 (%) | Ee of 7 (%) ^a | Config. of 7 |
|-------|----------|---------------------------------|-----------------------|---------------------------------|---------------------|
| 1 | a | Me | 22 | 7 | <i>S</i> |
| 2 | b | PhCH ₂ | 95 | 21 | <i>S</i> |
| 3 | c | 1-Naphthylmethyl | 87 | 58 | <i>S</i> |
| 4 | d | 2-Naphthylmethyl | Quant. | 66 | <i>S</i> |
| 5 | e | 9-Anthracenylmethyl | 98 | 91 | <i>S</i> |
| 6 | f | MeCO | Quant. | 89 | <i>R</i> |
| 7 | g | PhCO | 92 | 83 | <i>R</i> |
| 8 | h | 9-Anthracenyl-CO | 56 | 83 | <i>R</i> |
| 9 | i | <i>p</i> -NO ₂ -PhCO | Quant. | 88 | <i>R</i> |
| 10 | j | PhSO ₂ | 51 | 79 | <i>R</i> |

^a The ee was estimated by HPLC after removal of the chiral auxiliary.**Table 4.** Asymmetric addition reaction of silyl enol ethers with 9-(*N*-protected)- β -carboline

| Entry | R | R ¹ | R ² | Temperature (°C) | Time (h) | Product | Yield (%) | Ea (%) ^a | Config. of 8 |
|-------|---------------------------------|----------------|----------------|------------------|----------|-----------|-----------|---------------------|---------------------|
| 1 | Anthracenylmethyl | Me | H | 0 | 24 | 8a | 40 | 79 | <i>S</i> |
| 2 | Anthracenylmethyl | Ph | H | 0 | 2.5 | 8b | 79 | 86 | <i>S</i> |
| 3 | Anthracenylmethyl | OMe | Me | 0 | 0.5 | 8c | Quant. | 82 | <i>S</i> |
| 4 | Anthracenylmethyl | OBn | H | -40 | 12 | 8d | 81 | 88 | <i>S</i> |
| 5 | Anthracenylmethyl | SBn | H | -40 | 19 | 8e | 83 | 87 | <i>S</i> |
| 6 | MeCO | OBn | H | -78 | 40 | 8d | 93 | 76 | <i>R</i> |
| 7 | PhCO | OBn | H | -78 | 40 | 8d | Quant. | 76 | <i>R</i> |
| 8 | <i>p</i> -NO ₂ -PhCO | OBn | H | -78 | 40 | 8d | Quant. | 75 | <i>R</i> |

^a The ee was estimated by HPLC after removal of the chiral auxiliary.

Scheme 4.



Scheme 5.





Figure 1. Calculated PM3 structures of 2-(trichloroethoxycarbonyl)-9-(*N*-anthracenylmethylpyroglutamyl)- β -carbolinium cation (**11**). The optimized conformation in which the *Re* face is blocked $\Delta H_f=117.4253$ kcal/mol.




Figure 2. Calculated PM3 structures of 2-(trichloroethoxycarbonyl)-9-(*N*-anthracenylmethylpyroglutamyl)- β -carbolinium cation (**11**). A local minimal conformation in which the *Si* face is blocked $\Delta H_f=120.6484$ kcal/mol.

of a free carboxylic acid afforded methyl ester of tetrahydro- β -carboline 1-acetic acid **10**. The absolute configuration was determined as *S* in comparison with the specific rotation of the reported one.¹³ Thus, it was proved that the reaction proceeded in an *S* selective manner using the chiral auxiliary **5e** irrespective of the nucleophile to be allyltributyltin or silyl enol ether.

The unique stereoselectivities of the present reaction prompted us to consider factors controlling the stereochemistry. In the reaction using *N*-alkyl pyroglutamyl groups (entries 1–5 in Table 3), the increment of the steric hindrance linearly increased the stereoselectivity of the addition. These results indicate that the selectivity was originated from shielding of one side of the substrate plane. Thus, PM3 calculations¹⁴ were carried out for the intermediary *N*2-acylated quaternary salts of β -carboline whose optimized structures are shown in Figures 1 and 2.

In the optimized conformation in Figure 1, anthracenyl group is located on the *syn* position to the β -carboline group due to the π – π interaction of these two groups. The *Re* face of the reaction site (C1) of β -carboline ring is considerably shielded. A conformation in which the *Si* face is shielded was obtained as a local minimum structure as shown in Figure 2, but it is 3.22 kcal/mol less stable than that of Figure 1. Thus, the stereoselectivity using *N*-alkylpyroglutamyl groups could be accounted for by the shielding of the *Re* face by the anthracenyl group.

In the cases of *N*-acylpyroglutamyl groups (entries 6–10 of Table 3), however, the opposite stereoisomer was obtained. The bulkiness of the protecting group had little effect on the selectivity, and sterically less demanding *N*-acetyl derivative afforded the best result (entry 6).

These facts indicate that entirely different mechanism controls the stereochemistry. The PM3 calculation of the intermediates **12a** and **12b** showed that the carbonyl group A (in Figure 3) bends the methyl (in **12a**) or phenyl (in **12b**) group toward the far side of the reaction site because the carbonyl group A and another carbonyl group B in the pyroglutamyl ring tend to reside in an antiperiplanar position to each other probably due to dipolar repulsion. It is suggested from the conformation that the steric influence of the methyl or phenyl group is weak. Though the reason of *R* selectivity (*Re* face attack) in the case of the substrate **12** remained unclear, the coordination of the nucleophiles to two carbonyl groups A and C might cause the *Re* face attack because these two groups exist near the reaction site on the *Re* face.¹⁵ In fact, the addition of hexamethylphosphoric triamide (HMPA), which can act as a ligand for organometallic reagents, to the reaction system lowered the stereoselectivity.¹⁶ The result suggests that the coordination

12a (R=methyl): **12b** (R=phenyl)





Figure 3. The Optimized structure of 2-(trichloroethoxycarbonyl)-9-(*N*-acylpyroglutamyl)- β -carbolinium cation (**12a** and **12b**). (a) The optimized conformation of **12a**. $\Delta H_f=6.5927$ kcal/mol. (b) The optimized conformation of **12b**. $\Delta H_f=43.1778$ kcal/mol.

of the nucleophiles to the substrate might affect the selectivity.

3. Conclusion

In this paper, we described a new method for the asymmetric addition of allyltributyltin or silyl enol ethers to β -carboline at C-1 position using a novel chiral auxiliary derived from (*S*)-pyroglutamic acid. The auxiliary was readily recovered quantitatively by hydrolysis. Application of the adducts obtained by this method to the total synthesis of indole alkaloids is now under investigation.¹⁷

4. Experimental

4.1. General remarks

Melting points are uncorrected. ¹H and ¹³C NMR spectra of CDCl₃ and CD₃OD solutions were recorded at 500 and 125 MHz, respectively, with tetramethylsilane (TMS) as an internal standard. High-resolution mass spectra (FAB-HRMS) were measured using *p*-nitrobenzyl alcohol as a matrix.

4.2. Preparation of the chiral auxiliaries

4.2.1. *N*-Protection of *tert*-butyl (*S*)-pyroglutamate (**2**).

To the suspension of NaH (2 mmol) in THF (5 ml) was added *tert*-butyl (*S*)-pyroglutamate (**2**) (2 mmol), and the mixture was allowed to react for 5 min at room temperature, and an alkyl halide or acyl halide (2 mmol) was added to the mixture. The reaction was continued until the starting material was entirely consumed, then water was added and the mixture was extracted with CH₂Cl₂. The organic layer was dried over MgSO₄, and evaporated off to leave a residue, which was chromatographed on silica gel to give the product **3**.

4.2.2. *tert*-Butyl *N*-methyl(*S*)-pyroglutamate (**3a**).

Yield 94%; colorless plates from hexane; mp 69–71°C; [α]_D²⁰ = –10.8 (*c* 0.50, CHCl₃); ¹H NMR (CDCl₃) δ : 1.48 (9H, s), 2.01–2.08 (1H, m), 2.26–2.38 (2H, m), 2.43–2.51 (1H, m), 2.85 (3H, s), 3.98 (1H, dd, *J* = 8.7, 3.6 Hz); ¹³C NMR (CDCl₃) δ : 22.6, 28.0, 28.8, 29.3, 62.6, 82.3, 170.9, 175.3. Anal. calcd for C₁₀H₁₇NO₃: C, 60.28; H, 8.60; N, 7.03. Found: C, 60.31; H, 8.84; N, 6.95.

4.2.3. *tert*-Butyl *N*-benzyl(*S*)-pyroglutamate (**3b**).

Yield 81%; colorless needles from ^tPr₂O–AcOEt; mp 51.0–58.9°C; [α]_D²⁰ = +40.3 (*c* 0.51, CHCl₃); ¹H NMR (CDCl₃) δ : 1.44 (9H, s), 1.99–2.06 (1H, m), 2.16–2.26 (1H, m), 2.40 (1H, ddd, *J* = 13.6, 9.6, 4.0 Hz), 2.51–2.60 (1H, m), 3.83 (1H, dd, *J* = 9.2, 3.3 Hz), 3.96 (1H, d, *J* = 14.7 Hz), 5.06 (1H, d, *J* = 14.7 Hz), 7.20–7.23 (2H, m), 7.26–7.35 (3H, m); ¹³C NMR (CDCl₃) δ : 22.9, 28.0, 29.7, 45.6, 59.6, 82.2, 127.6, 128.4, 128.6, 135.8, 170.6, 174.9. Anal. calcd for C₁₆H₂₁NO₃: C, 69.79; H, 7.69; N, 5.09. Found: C, 69.65; H, 7.55; N, 5.09.

4.2.4. *tert*-Butyl *N*-(naphthalen-1-ylmethyl)-(*S*)-pyroglutamate (**3c**).

Yield 83%; colorless needles from hexane;

mp 76–77°C; [α]_D²⁰ = +51.5 (*c* 0.53, CHCl₃); ¹H NMR (CDCl₃) δ : 1.40 (9H, s), 1.90–1.98 (1H, m), 2.09 (1H, ddd, *J* = 18.8, 13.3, 9.2 Hz), 2.40 (1H, ddd, *J* = 16.9, 9.6, 3.8 Hz), 2.52–2.62 (1H, m), 3.61 (1H, dd, *J* = 9.2, 3.2 Hz), 4.39 (1H, d, *J* = 14.6 Hz), 5.56 (1H, d, *J* = 14.6 Hz), 7.34 (1H, dd, *J* = 6.8, 1.0 Hz), 7.40 (1H, dd, *J* = 8.1, 7.0 Hz), 7.48–7.56 (2H, m), 7.81–7.88 (2H, m), 8.08 (1H, dt, *J* = 6.8, 1.1 Hz); ¹³C NMR (CDCl₃) δ : 22.9, 28.0, 29.8, 43.8, 59.4, 82.0, 123.7, 125.0, 126.0, 126.7, 128.0, 128.5, 128.8, 131.3, 131.6, 133.7, 170.7, 174.5. Anal. calcd for C₂₀H₂₃NO₃: C, 73.82; H, 7.12; N, 4.30. Found: C, 73.84; H, 7.22; N, 4.30.

4.2.5. *tert*-Butyl *N*-(naphthalen-2-ylmethyl)-(*S*)-pyroglutamate (**3d**).

Yield 83%; colorless needles from hexane; mp 98–99°C; [α]_D²⁰ = +69.7 (*c* 0.54, CHCl₃); ¹H NMR (CDCl₃) δ : 1.41 (9H, s), 1.98–2.05 (1H, m), 2.19 (1H, ddd, *J* = 18.7, 13.2, 9.2 Hz), 2.42 (1H, ddd, *J* = 16.9, 9.7, 4.0 Hz), 2.53–2.62 (1H, m), 3.83 (1H, dd, *J* = 9.2, 3.3 Hz), 4.14 (1H, d, *J* = 14.7 Hz), 5.21 (1H, d, *J* = 14.7 Hz), 7.35 (1H, dd, *J* = 8.4, 1.7 Hz), 7.43–7.50 (2H, m), 7.65 (1H, s), 7.77–7.83 (3H, m); ¹³C NMR (CDCl₃) δ : 22.8, 27.9, 29.6, 45.7, 59.4, 82.0, 125.8, 126.1, 126.2, 127.3, 127.4, 127.5, 128.4, 132.6, 133.0, 133.2, 170.5, 174.8. Anal. calcd for C₂₀H₂₃NO₃: C, 73.82; H, 7.12; N, 4.30. Found: C, 73.74; H, 7.23; N, 4.32.

4.2.6. *tert*-Butyl *N*-(anthracen-9-ylmethyl)-(*S*)-pyroglutamate (**3e**).

Yield 75%; Yellow needles from isopropyl ether; mp 169–172°C; [α]_D²⁰ = +141.4 (*c* 0.48, CHCl₃); ¹H NMR (CDCl₃) δ : 1.35 (9H, s), 1.82–1.89 (1H, m), 1.90–2.01 (1H, m), 2.38 (1H, ddd, *J* = 16.9, 9.3, 2.6 Hz), 2.50–2.59 (1H, m), 3.43 (1H, dd, *J* = 9.5, 2.0 Hz), 5.22 (1H, d, *J* = 15.3 Hz), 5.94 (1H, d, *J* = 15.3 Hz), 7.47 (2H, ddd, *J* = 7.7, 6.4, 1.1 Hz), 7.52 (2H, ddd, *J* = 8.1, 6.4, 1.5 Hz), 8.01 (2H, dd, *J* = 8.1, 1.5 Hz), 8.33 (2H, dd, *J* = 7.7, 1.1 Hz), 8.46 (1H, s); ¹³C NMR (CDCl₃) δ : 23.6, 27.9, 29.5, 37.5, 58.7, 82.0, 123.9, 125.0, 126.50, 126.52, 128.3, 129.0, 131.0, 131.2, 171.2, 174.5. Anal. calcd for C₂₄H₂₅NO₃: C, 76.77; H, 6.71; N, 3.73. Found: C, 76.56; H, 6.70; N, 3.49.

4.2.7. *tert*-Butyl *N*-acetyl(*S*)-pyroglutamate (**3f**).

Yield 75%; colorless oil; [α]_D²³ = –37.6 (*c* 0.61, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ : 1.47 (9H, s), 2.01–2.07 (1H, m), 2.25–2.36 (1H, m), 2.52 (3H, s), 2.52–2.59 (1H, m), 2.66–2.76 (1H, m), 4.63 (1H, dd, *J* = 9.4, 2.2 Hz); ¹³C NMR (100 MHz, CDCl₃) δ : 21.2, 24.6, 27.8, 31.8, 58.4, 82.3, 170.1, 170.9, 174.6. HRMS (FAB⁺) *m/z*: Calcd for C₁₁H₁₈O₄N 228.1236, found 228.1218.

4.2.8. *tert*-Butyl *N*-benzoyl(*S*)-pyroglutamate (**3g**).

Yield 74%; colorless needles from hexane–dichloromethane; mp 150.9–151.4°C; [α]_D²³ = –30.6 (*c* 0.35, CHCl₃); ¹H NMR (CDCl₃) δ : 1.98 (9H, s), 2.10 (1H, ddt, *J* = 13.4, 9.0, 4.7 Hz), 2.42 (1H, dq, *J* = 13.4, 9.0 Hz), 2.55 (1H, ddd, *J* = 17.5, 9.0, 4.7 Hz), 2.70 (1H, dt, *J* = 17.5, 9.0 Hz), 4.77 (1H, dd, *J* = 9.0, 4.7 Hz), 7.41 (2H, t, *J* = 7.6 Hz), 7.52 (1H, t, *J* = 7.6 Hz), 7.66 (2H, d, *J* = 7.6 Hz); ¹³C NMR (CDCl₃) δ : 21.8, 27.9, 31.8, 59.5, 82.5, 127.8, 129.1, 132.2, 133.9, 170.0, 170.4, 173.6. Anal. calcd for C₁₆H₁₉NO₄: C, 66.42; H, 6.62; N, 4.84. Found: C, 66.38; H, 6.62; N, 4.84.

4.2.9. *tert*-Butyl *N*-(9-anthracenecarbonyl)-(*S*)-pyroglutamate (**3h**).

Yield 83%; mp 82.9–84.3°C; [α]_D²³ = –88.1 (*c* 0.60, CHCl₃); ¹H NMR (CDCl₃) δ : 1.65

(9H, s), 2.08–2.14 (1H, m), 2.29–2.40 (2H, m), 2.51–2.62 (1H, m), 5.08 (1H, dd, $J=9.2, 3.1$ Hz), 7.41–7.50 (3H, m), 7.54–7.57 (1H, m), 7.77 (1H, d, $J=7.6$ Hz), 8.02 (2H, d, $J=8.2$ Hz), 8.26 (1H, d, $J=8.5$ Hz), 8.52 (1H, s); ^{13}C NMR (CDCl_3) δ : 21.4, 27.9, 31.2, 58.6, 82.7, 123.9, 124.7, 125.1, 125.3, 126.5, 126.7, 127.6, 128.2, 128.3, 128.4, 128.7, 129.9, 130.8, 130.9, 169.7, 170.1, 172.2. Anal. calcd for $\text{C}_{24}\text{H}_{23}\text{NO}_4$: C, 74.02; H, 5.95; N, 3.60. Found: C, 73.87; H, 6.23; N, 3.36.

4.2.10. *tert*-Butyl *N*-(*p*-nitrobenzoyl)-(*S*)-pyroglutamate (3i). Yield 69%; Pale yellow powder from hexane–dichloromethane; mp 111.1–120.0°C; $[\alpha]_{\text{D}}^{23}=-17.3$ (c 0.5, CHCl_3); ^1H NMR (CDCl_3) δ : 1.51 (9H, s), 2.17 (1H, ddt, $J=13.2, 9.4, 4.2$ Hz), 2.48 (1H, ddt, $J=13.2, 9.2, 9.0$ Hz), 2.59 (1H, ddd, $J=17.8, 9.3, 4.5$ Hz), 2.74 (1H, dt, $J=18.0$ Hz), 4.82 (1H, dd, $J=8.9, 3.9$ Hz), 7.77 (2H, d, $J=9.0$ Hz), 8.27 (2H, d, $J=9.0$ Hz); ^{13}C NMR (CDCl_3) δ : 21.8, 27.9, 31.5, 59.0, 83.0, 123.1, 129.6, 139.9, 149.5, 168.5, 169.6, 173.7. Anal. calcd for $\text{C}_{16}\text{H}_{18}\text{N}_2\text{O}_6$: C, 57.48; H, 5.43; N, 8.38. Found: C, 57.54; H, 5.31; N, 8.23.

4.2.11. *tert*-Butyl *N*-benzenesulfonyl-(*S*)-pyroglutamate (3j). Yield 69%; colorless viscous oil; $[\alpha]_{\text{D}}^{20}=-47.8$ (c 0.52, CHCl_3); ^1H NMR (CDCl_3) δ : 1.49 (9H, s), 2.01–2.08 (1H, m), 2.33–2.45 (2H, m), 2.46–2.59 (1H, m), 4.74 (1H, dd, $J=9.0, 2.6$ Hz), 7.52 (2H, t, $J=8.0$ Hz), 7.64 (1H, tt, $J=8.0, 1.3$ Hz), 8.08 (2H, dd, $J=8.0, 1.3$ Hz); ^{13}C NMR (CDCl_3) δ : 23.2, 27.7, 30.3, 60.0, 82.7, 128.3, 128.5, 133.8, 137.7, 169.4, 172.4. HRMS (FAB $^+$): Calcd for $\text{C}_{15}\text{H}_{20}\text{NO}_5\text{S}$ (M+H) $^+$: 326.1062. Found: 326.1031.

4.3. Transformation of 3 to corresponding carboxylic acid 4

To the CH_2Cl_2 solution of *N*-protected *tert*-butyl (*S*)-pyroglutamate 3, trifluoroacetic acid (5 equiv.) was added dropwise, and the mixture was allowed to react at room temperature. Then CH_2Cl_2 was added and the mixture was extracted with saturated aqueous NaHCO_3 . The aqueous layer was acidified with dil. HCl, and extracted with CH_2Cl_2 . The organic layer was dried over MgSO_4 , and evaporated off to leave a residue. The residue was suspended in hexane to precipitate crystals, which was separated from the solution by filtration, and dried under vacuum to give *N*-protected pyroglutamic acid 4.

4.3.1. *N*-Methyl-(*S*)-pyroglutamic acid (4a). Yield 71%; colorless prisms from $i\text{Pr}_2\text{O}$ –AcOEt; mp 148–150°C; $[\alpha]_{\text{D}}^{20}=-20.8$ (c 0.15, CHCl_3); ^1H NMR (CDCl_3) δ : 2.16–2.24 (1H, m), 2.38–2.64 (3H, m), 2.92 (3H, s), 4.19 (1H, dd, $J=9.2, 3.4$ Hz), 10.61 (1H, bs); ^{13}C NMR (CDCl_3) δ : 20.8, 22.8, 29.4, 62.1, 174.0, 176.9. Anal. calcd for $\text{C}_6\text{H}_9\text{NO}_3$: C, 50.35; H, 6.34; N, 9.79. Found: C, 50.32; H, 6.34; N, 9.76.

4.3.2. *N*-Benzyl-(*S*)-pyroglutamic acid (4b). The mp and NMR spectra of this compound were identical to those of the reported data.¹⁸ Yield 91%; colorless powder; mp 85–88°C (lit.¹⁸ mp 92–93°C); $[\alpha]_{\text{D}}^{20}=+78.6$ (c 0.50, CHCl_3); ^1H NMR (CDCl_3) δ : 2.13–2.21 (1H, m), 2.30 (1H, ddd, $J=18.9, 13.4, 9.3$ Hz), 2.52 (1H, ddd, $J=17.1, 9.3, 3.7$ Hz), 2.60–2.69 (1H, m), 3.99 (1H, d, $J=14.8$ Hz), 4.03 (1H, dd, $J=9.3, 3.1$ Hz), 5.16 (1H, d, $J=14.8$ Hz), 7.21–7.23 (2H, m), 7.26–7.35 (3H, m), 10.06 (1H, bs).

4.3.3. *N*-(Naphthalen-1-ylmethyl)-(*S*)-pyroglutamic acid (4c). Yield 87%; colorless needles from isopropyl ether; mp 184–185°C; $[\alpha]_{\text{D}}^{20}=+97.5$ (c 0.53, CHCl_3); ^1H NMR (CD_3OD) δ : 1.97–2.08 (1H, m), 2.10–2.18 (1H, m), 2.35–2.43 (1H, m), 2.50–2.58 (1H, m), 3.72 (1H, dd, $J=9.4, 3.1$ Hz), 4.36 (1H, d, $J=14.7$ Hz), 5.56 (1H, d, $J=14.7$ Hz), 7.35–7.43 (2H, m), 7.49–7.51 (2H, m), 7.83–7.89 (2H, m), 8.01–8.04 (1H, m); ^{13}C NMR (CD_3OD) δ : 23.8, 30.7, 44.6, 60.0, 124.2, 126.1, 126.9, 127.5, 128.9, 129.7, 129.9, 132.0, 132.7, 135.2, 174.4, 177.2. Anal. calcd for $\text{C}_{16}\text{H}_{15}\text{NO}_3$: C, 71.36; H, 5.61; N, 5.20. Found: C, 71.18; H, 5.42; N, 5.15.

4.3.4. *N*-(Naphthalen-2-ylmethyl)-(*S*)-pyroglutamic acid (4d). Yield 97%; colorless needles from hexane– $i\text{Pr}_2\text{O}$; mp 149–152°C; $[\alpha]_{\text{D}}^{20}=+73.6$ (c 0.50, CH_3OH); ^1H NMR (CDCl_3) δ : 2.11–2.17 (1H, m), 2.25 (1H, ddd, $J=18.9, 13.4, 9.5$ Hz), 2.44 (1H, ddd, $J=16.8, 9.5, 3.7$ Hz), 2.56–2.63 (1H, m), 3.96 (1H, dd, $J=9.3, 3.3$ Hz), 4.18 (1H, d, $J=14.9$ Hz), 5.24 (1H, d, $J=14.9$ Hz), 7.37 (1H, dd, $J=8.5, 1.8$ Hz), 7.44–7.49 (2H, m), 7.68 (1H, s), 7.79–7.82 (3H, m); ^{13}C NMR (CDCl_3) δ : 22.9, 29.7, 45.6, 58.6, 126.0, 126.2, 126.4, 127.3, 127.6, 127.8, 128.6, 132.8, 133.3, 133.6, 173.7, 175.4. Anal. calcd for $\text{C}_{16}\text{H}_{15}\text{NO}_3$: C, 71.36; H, 5.61; N, 5.20. Found: C, 71.10; H, 5.59; N, 5.18.

4.3.5. *N*-(Anthracen-9-ylmethyl)-(*S*)-pyroglutamic acid (4e). Yield 94%; Pale green prisms from ethanol; mp 277–280°C; $[\alpha]_{\text{D}}^{20}=+151.2$ (c 0.50, CHCl_3); ^1H NMR (CDCl_3) δ : 1.83–2.00 (2H, m), 2.31 (1H, ddd, $J=16.9, 9.5, 2.4$ Hz), 2.39–2.48 (1H, m), 3.41 (1H, dd, $J=9.4, 1.7$ Hz), 5.13 (1H, d, $J=15.1$ Hz), 5.84 (1H, d, $J=15.1$ Hz), 7.55 (2H, t, $J=8.2$ Hz), 7.60 (2H, t, $J=8.2$ Hz), 8.12 (2H, d, $J=8.2$ Hz), 8.35 (2H, d, $J=8.2$ Hz), 8.62 (1H, s); ^{13}C NMR (CDCl_3) δ : 22.7, 28.9, 36.8, 57.5, 123.4, 125.0, 126.4, 126.6, 128.0, 129.0, 130.4, 130.7, 173.4, 173.7. Anal. calcd for $\text{C}_{20}\text{H}_{17}\text{NO}_3$: C, 75.22; H, 5.37; N, 4.39. Found: C, 74.86; H, 5.18; N, 4.33.

4.3.6. *N*-Acetyl-(*S*)-pyroglutamic acid (4f). Yield 73%; colorless powder from hexane; mp 75.9–77.0°C; $[\alpha]_{\text{D}}^{20}=-29.90$ (c 0.54, CHCl_3); ^1H NMR (400 MHz, CDCl_3) δ : 2.19 (1H, ddt, $J=13.4, 9.5, 3.0$ Hz), 2.33–2.48 (1H, m), 2.55 (3H, s), 2.60 (1H, ddd, $J=17.8, 9.3, 3.1$ Hz), 2.76 (1H, dt, $J=17.8, 10.1$ Hz), 4.79 (1H, dd, $J=9.7, 2.6$ Hz), 9.16 (1H, bs); ^{13}C NMR (100 MHz, CDCl_3) δ : 21.1, 24.5, 31.7, 57.5, 171.3, 174.4, 176.2. Anal. calcd for $\text{C}_7\text{H}_9\text{NO}_4$: C, 49.12; H, 5.30; N, 8.18. Found: C, 49.01; H, 5.12; N, 8.01.

4.3.7. *N*-Benzoyl-(*S*)-pyroglutamic acid (4g). Yield 90%; colorless needles from hexane–ethyl acetate; mp 168.2–168.6°C; $[\alpha]_{\text{D}}^{25}=+15.43$ (c 0.3, CH_3OH); ^1H NMR (CDCl_3) δ : 2.27 (1H, ddt, $J=13.2, 9.2, 4.5$ Hz), 2.51 (1H, dq, $J=13.2, 9.2$ Hz), 2.62 (1H, ddd, $J=17.7, 9.2, 4.5$ Hz), 2.78 (1H, dt, $J=17.7, 9.2$ Hz), 4.92 (1H, dd, $J=9.2, 4.5$ Hz), 7.42 (2H, tt, $J=7.5, 1.4$ Hz), 7.54 (1H, tt, $J=7.5, 1.5$ Hz), 7.65–7.68 (2H, m); ^{13}C NMR (CDCl_3) δ : 21.7, 31.6, 58.5, 127.9, 129.2, 132.5, 133.4, 170.5, 173.3, 175.5. Anal. calcd for $\text{C}_{12}\text{H}_{11}\text{NO}_4$: C, 61.80; H, 4.75; N, 6.01. Found: C, 61.77; H, 4.54; N, 5.80.

4.3.8. *N*-(Anthracene-9-carbonyl)-(*S*)-pyroglutamic acid

(4h). Yield 85%; Pale yellow powder; mp 150–155°C; $[\alpha]_D^{17} = -36.38$ (*c* 0.40, CH₃OH); ¹H NMR (CDCl₃) δ: 2.32 (1H, ddt, *J*=12.6, 9.8, 2.7 Hz), 2.40–2.47 (1H, m), 2.54 (1H, dq, *J*=12.9, 9.2 Hz), 2.67 (1H, dt, *J*=16.7, 9.5 Hz), 5.24 (1H, dd, *J*=9.2, 2.6 Hz), 7.43–7.51 (4H, m), 7.73–7.75 (1H, m), 8.00–8.04 (2H, m), 8.22 (1H, d, *J*=7.9 Hz), 8.52 (1H, s); ¹³C NMR (CDCl₃) δ: 21.8, 31.5, 57.9, 123.9, 124.8, 125.3, 125.6, 126.8, 126.9, 127.7, 128.4, 128.5, 128.6, 128.9, 130.0, 130.9, 131.1, 170.3, 172.7, 173.0. HRMS (FAB⁺) *m/z*: Calcd for C₂₀H₁₆NO₄ (M+H)⁺ 334.1079, found 334.1061.

4.3.9. *N*-(*p*-Nitrobenzoyl)-(S)-pyroglutamic acid (4i). Yield 91%; Pale yellow powder; mp 150.4–151.0°C; $[\alpha]_D^{20} = +12.46$ (*c* 0.5, CH₃OH); ¹H NMR (CDCl₃) δ: 2.32 (1H, ddt, *J*=13.1, 9.4, 3.7 Hz), 2.57 (1H, ddt, *J*=13.3, 9.3, 9.1 Hz), 2.66 (1H, ddd, *J*=17.7, 8.9, 3.7 Hz), 2.79 (1H, ddt, *J*=17.6, 9.0, 8.9 Hz), 4.98 (1H, dd, *J*=9.1, 3.6 Hz), 7.77 (2H, d, *J*=9.0 Hz), 8.29 (2H, d, *J*=9.0 Hz); ¹³C NMR (CDCl₃+CD₃OD) δ: 21.9, 31.6, 58.4, 123.2, 129.6, 140.0, 149.5, 168.8, 172.6, 174.3. Anal. calcd for C₁₂H₁₀N₂O₆: C, 51.80; H, 3.62; N, 10.07. Found: C, 51.45; H, 3.30; N, 9.68.

4.3.10. *N*-(Benzenesulfonyl)-(S)-pyroglutamic acid (4j). Yield 76%; colorless powder; mp 158–160.5°C; $[\alpha]_D^{20} = -41.0$ (*c* 0.50, CH₃OH); ¹H NMR (CDCl₃) δ: 2.20–2.29 (1H, m), 2.43–2.70 (3H, m), 4.94 (1H, dd, *J*=9.2, 2.5 Hz), 5.72 (1H, br), 7.56 (2H, t, *J*=8.0 Hz), 7.68 (1H, t, *J*=8.0 Hz), 8.11 (2H, dd, *J*=8.0, 1.3 Hz); ¹³C NMR (CDCl₃) δ: 23.4, 30.5, 59.0, 128.7, 128.8, 134.3, 137.5, 172.3, 175.0. Anal. calcd for C₁₁H₁₁NO₅S: C, 49.06; H, 4.12; N, 5.20. Found: C, 48.97; H, 3.74; N, 5.15.

4.4. The synthesis of 9-pyroglutaminyl-β-carbolines 5

To the CH₂Cl₂ (1 ml) solution of *N*-substituted pyroglutamic acid **4** (0.5 mmol) and β-carboline (0.5 mmol) was added EDCI (0.6 mmol), and the mixture was allowed to react for 1–3 h at room temperature. Then the mixture was chromatographed on silica gel (AcOEt) to give the product.

4.4.1. 9-(*N*-Methyl-(S)-pyroglutamyl)-β-carboline (5a). Yield 86%; colorless powder; mp 175–178°C; $[\alpha]_D^{20} = -148.9$ (*c* 0.30, CH₃OH); ¹H NMR (CDCl₃) δ: 2.31–2.37 (1H, m), 2.51–2.80 (3H, m), 2.95 (3H, s), 5.19 (1H, dd, *J*=9.3, 1.8 Hz), 7.52 (1H, t, *J*=7.3 Hz), 7.68 (1H, ddd, *J*=8.6, 7.3, 1.3 Hz), 7.94 (1H, dd, *J*=5.1, 0.9 Hz), 8.12 (1H, dd, *J*=7.3, 0.6 Hz), 8.18 (1H, br), 8.68 (1H, d, *J*=5.1 Hz), 9.55 (1H, s); ¹³C NMR (CDCl₃) δ: 23.6, 28.8, 29.2, 63.4, 114.1, 116.1, 121.5, 122.0, 124.6, 132.8, 134.6, 137.6, 138.2, 144.0, 147.5, 170.1, 174.9. Anal. calcd for C₁₇H₁₅N₃O₂: C, 69.61; H, 5.15; N, 14.33. Found: C, 69.35; H, 5.02; N, 14.15.

4.4.2. 9-(*N*-Benzyl-(S)-pyroglutamyl)-β-carboline (5b). Yield 99%; colorless needles from Et₂O–AcOEt; mp 175–178°C; $[\alpha]_D^{20} = -124.7$ (*c* 0.13, CHCl₃); ¹H NMR (CDCl₃) δ: 2.26–2.32 (1H, m), 2.55–2.64 (2H, m), 2.66–2.75 (1H, m), 4.00 (1H, d, *J*=14.8 Hz), 5.01 (1H, dd, *J*=8.9, 1.9 Hz), 5.22 (1H, d, *J*=14.8 Hz), 7.12–7.18 (5H, m), 7.48 (1H, t, *J*=8.4 Hz), 7.60 (1H, t, *J*=8.4 Hz), 7.85–8.20 (1H, br), 7.91 (1H, dd, *J*=5.1, 0.9 Hz), 8.09 (1H, d, *J*=8.4 Hz), 8.64 (1H, d, *J*=5.1 Hz), 9.31 (1H, bs); ¹³C NMR (CDCl₃) δ:

23.8, 29.3, 45.9, 60.2, 114.2, 116.1, 121.5, 124.5, 124.6, 127.7, 128.2, 128.7, 130.3, 132.9, 134.6, 135.3, 137.4, 138.3, 143.9, 170.6, 174.8. Anal. calcd for C₂₃H₁₉N₃O₂: C, 74.78; H, 5.18; N, 11.37. Found: C, 74.47; H, 4.79; N, 11.46.

4.4.3. 9-[*N*-(Naphthalen-1-ylmethyl)-(S)-pyroglutamyl]-β-carboline (5c). Yield 77%; colorless powder; mp 88–92°C; $[\alpha]_D^{20} = -114.1$ (*c* 0.17, CHCl₃); ¹H NMR (CDCl₃) δ: 2.21 (1H, ddt, *J*=11.9, 9.5, 2.4 Hz), 2.46 (1H, ddd, *J*=19.2, 13.1, 9.5 Hz), 2.60 (1H, ddd, *J*=16.8, 9.5, 2.4 Hz), 2.76 (1H, dt, *J*=16.8, 9.5 Hz), 4.47 (1H, d, *J*=14.6 Hz), 4.79 (1H, dd, *J*=9.5, 2.4 Hz), 5.62 (1H, d, *J*=14.6 Hz), 6.95 (1H, dd, *J*=8.2, 7.0 Hz), 7.06 (1H, d, *J*=7.0 Hz), 7.40–7.54 (4H, m), 7.55 (1H, d, *J*=7.9 Hz), 7.72–7.75 (1H, m), 7.87 (1H, dd, *J*=4.9, 0.9 Hz), 8.05 (2H, d, *J*=8.9 Hz), 8.61 (1H, d, *J*=4.9 Hz); ¹³C NMR (CDCl₃) δ: 23.5, 29.5, 43.9, 59.8, 114.2, 121.5, 123.5, 124.7, 124.8, 126.2, 126.9, 127.8, 128.7, 129.0, 130.3, 130.9, 131.6, 132.8, 133.7, 144.2, 170.9, 174.8. Anal. calcd for C₂₇H₂₁N₃O₂·1/2H₂O: C, 75.68; H, 5.17; N, 9.81. Found: C, 75.61; H, 5.21; N, 9.37.

4.4.4. 9-[*N*-(Naphthalen-2-ylmethyl)-(S)-pyroglutamyl]-β-carboline (5d). Yield 88%; colorless needles from ⁱPr₂O–AcOEt; mp 149–152°C; $[\alpha]_D^{20} = -104.2$ (*c* 0.52, CHCl₃); ¹H NMR (CDCl₃) δ: 2.31–2.35 (1H, m), 2.55–2.67 (2H, m), 2.71–2.81 (1H, m), 4.19 (1H, d, *J*=14.9 Hz), 5.04 (1H, dd, *J*=9.0, 2.4 Hz), 5.27 (1H, d, *J*=14.9 Hz), 7.26–7.43 (6H, m), 7.50 (1H, t, *J*=7.4 Hz), 7.67 (2H, t, *J*=8.1 Hz), 7.81 (1H, d, *J*=4.9 Hz), 7.86 (1H, br), 7.99 (1H, d, *J*=7.7 Hz), 8.57 (1H, d, *J*=4.9 Hz), 9.29 (1H, bs); ¹³C NMR (CDCl₃) δ: 23.8, 29.4, 46.2, 60.1, 114.1, 116.0 (br), 121.5, 124.4, 124.6, 125.92, 125.94, 126.1, 127.3, 127.4, 128.7, 130.2, 132.57, 132.64, 132.8, 132.9, 134.5 (br), 137.3 (br), 138.2 (br), 143.7, 170.7, 174.9. Anal. calcd for C₂₇H₂₁N₃O₂: C, 77.31; H, 5.05; N, 10.02. Found: C, 77.07; H, 4.80; N, 9.98.

4.4.5. 9-[*N*-(Anthracen-9-ylmethyl)-(S)-pyroglutamyl]-β-carboline (5e). Yield 95%; colorless powder; mp 190–193°C (decomp.); $[\alpha]_D^{20} = -75.9$ (*c* 0.51, CHCl₃); ¹H NMR (CDCl₃, 60°C) δ: 2.10–2.15 (1H, m), 2.28–2.36 (1H, m), 2.57 (1H, ddd, *J*=16.8, 9.5, 2.1 Hz), 2.82 (1H, dt, *J*=17.1, 9.5 Hz), 4.56 (1H, dd, *J*=9.1, 1.5 Hz), 5.34 (1H, d, *J*=15.3 Hz), 5.79 (1H, d, *J*=15.3 Hz), 7.04 (2H, t, *J*=7.6 Hz), 7.15 (2H, t, *J*=8.2 Hz), 7.35 (1H, br), 7.65 (2H, d, *J*=8.5 Hz), 7.71 (1H, d, *J*=4.9 Hz), 7.88–7.90 (1H, m), 8.02 (1H, s), 8.07 (2H, d, *J*=8.9 Hz), 8.51 (1H, br); ¹³C NMR (CDCl₃, 60°C) δ: 23.7, 29.4, 37.8, 59.3, 113.9, 121.2 (br), 123.3, 124.5 (br), 124.9, 125.5, 126.6, 128.4, 129.1, 130.0 (br), 130.9, 131.1, 132.8 (br), 143.7, 171.4, 174.9. Anal. calcd for C₃₁H₂₃N₃O₂: C, 79.30; H, 4.94; N, 8.95. Found: C, 78.93; H, 5.00; N, 8.77.

4.4.6. 9-(*N*-Acetyl-(S)-pyroglutamyl)-β-carboline (5f). Yield 71%; colorless needles from ⁱPr₂O–CH₂Cl₂; mp 195–196°C; $[\alpha]_D^{20} = -68.39$ (*c* 0.59, CHCl₃); ¹H NMR (CDCl₃) δ: 2.30–2.38 (1H, m), 2.57–2.79 (2H, m), 2.63 (3H, s), 7.50 (1H, dt, *J*=7.6, 0.8 Hz), 7.64 (1H, ddd, *J*=8.6, 7.3, 1.3 Hz), 7.93 (1H, dd, *J*=5.1, 1.1 Hz), 8.11 (1H, ddd, *J*=7.8, 1.3, 0.6 Hz), 8.17 (1H, bs), 8.66 (1H, d, *J*=5.1 Hz), 9.50 (1H, bs); ¹³C NMR (125 MHz, CDCl₃) δ: 21.7, 24.6, 31.6, 59.0, 114.5, 116.4, 121.7, 124.7, 124.8, 130.5, 133.3, 135.0, 137.5, 138.7, 143.8, 170.2, 171.2, 174.2. Anal. calcd for C₁₈H₁₅N₃O₃: C, 67.28; H, 4.71; N, 13.08. Found: C, 67.00; H, 4.50; N, 12.85.

4.4.7. 9-[N-(Benzoyl)-(S)-pyroglutamyl]- β -carboline (5g). Yield 99%; colorless powder from hexane; mp 170.0–171.2°C; $[\alpha]_D^{25} = +13.91$ (*c* 0.5, CHCl₃); ¹H NMR (CDCl₃) δ : 2.36–2.43 (1H, m), 2.68–2.79 (2H, m), 2.91–3.03 (1H, m), 6.00 (1H, dd, *J*=8.9, 2.3 Hz), 7.43 (2H, t, *J*=7.6 Hz), 7.49–7.57 (2H, m), 7.65–7.73 (3H, m), 7.98 (1H, dd, *J*=5.1, 0.9 Hz), 8.12 (1H, d, *J*=7.1 Hz), 8.2 (1H, d, *J*=5.9 Hz), 8.67 (1H, d, *J*=5.1 Hz), 9.57 (1H, bs); ¹³C NMR (CDCl₃) δ : 22.1, 31.4, 59.9, 114.3, 116.3, 121.6, 124.7, 124.7, 127.8, 129.2, 130.3, 132.3, 133.0, 133.3, 135.0, 137.8, 138.5, 144.1, 170.30, 170.34, 173.1. Anal. calcd for C₂₃H₁₇N₃O₃: C, 72.05; H, 4.47; N, 10.96. Found: C, 72.24; H, 4.21; N, 10.90.

4.4.8. 9-[N-(Anthracene-9-carbonyl)-(S)-pyroglutamyl]- β -carboline (5h). Yield 73%; colorless powder; mp 180–183°C (decomp); $[\alpha]_D^{25} = -139.36$ (*c* 0.6, CHCl₃); ¹H NMR (CDCl₃) δ : 2.44–2.48 (1H, m), 2.53–2.61 (1H, m), 2.80–2.88 (2H, m), 6.41 (1H, dd, *J*=9.0, 1.4 Hz), 7.45–7.57 (4H, m), 7.65 (1H, t, *J*=7.2 Hz), 7.76 (1H, td, *J*=7.8, 1.1 Hz), 7.84 (1H, d, *J*=8.2 Hz), 8.02–8.05 (3H, m), 8.16 (1H, d, *J*=7.6 Hz), 8.30 (1H, bs), 8.34 (1H, d, *J*=8.9 Hz), 8.54 (1H, s), 8.66 (1H, d, *J*=5.2 Hz), 9.77 (1H, bs); ¹³C NMR (125 MHz, CDCl₃) δ : 22.1, 31.1, 59.1, 114.5, 116.4, 121.8, 123.8, 124.9, 125.2, 125.7, 126.7, 127.2, 127.7, 128.45, 128.53, 128.7, 129.0, 129.4, 130.5, 130.8, 131.1, 133.3, 135.2, 138.0, 138.7, 144.2, 170.1, 170.2, 171.8. Anal. calcd for C₃₁H₂₁N₃O₃: C, 77.00; H, 4.38; N, 8.69. Found: C, 76.80; H, 4.11; N, 8.58.

4.4.9. 9-[N-(*p*-Nitrobenzoyl)-(S)-pyroglutamyl]- β -carboline (5i). Yield 74%; Pale yellow needles from ^tPr₂O–CH₂Cl₂; mp 223–225°C; $[\alpha]_D^{20} = +8.12$ (*c* 0.30, CHCl₃); ¹H NMR (CDCl₃) δ : 2.42–2.50 (1H, m), 2.73–2.87 (2H, m), 2.91–3.04 (1H, m), 6.07 (1H, dd, *J*=9.0, 2.0 Hz), 7.54 (1H, td, *J*=7.6, 0.6 Hz), 7.70 (1H, td, *J*=7.9, 1.3 Hz), 7.85 (2H, d, *J*=8.8 Hz), 7.98 (1H, dd, *J*=5.1, 0.7 Hz), 8.15 (1H, dd, *J*=7.8, 0.6 Hz), 8.23 (1H, bs), 8.31 (2H, d, *J*=8.8 Hz), 8.70 (2H, d, *J*=5.1 Hz), 9.57 (1H, bs); ¹³C NMR (CDCl₃) δ : 22.2, 31.2, 59.7, 114.5, 116.4, 121.8, 123.2, 124.96, 125.01, 129.7, 130.6, 135.0, 137.8, 138.6, 139.4, 144.4, 149.6, 168.4, 169.8, 173.3. HRMS (FAB⁺) *m/z*: Calcd for C₂₃H₁₇O₅N₄ (M+H)⁺ 429.1199, found 429.1245.

4.4.10. 9-[N-(Benzenesulfonyl)-(S)-pyroglutamyl]- β -carboline (5j). Yield 91%; colorless plates from ^tPr₂O–AcOEt; mp 203.1–204.0°C; $[\alpha]_D^{20} = -94.6$ (*c* 0.29, CHCl₃); ¹H NMR (CDCl₃) δ : 2.32–2.40 (1H, m), 2.57–2.66 (1H, m), 2.71–2.85 (2H, m), 6.07 (1H, dd, *J*=9.2, 1.5 Hz), 7.53–7.60 (3H, m), 7.69–7.75 (2H, m), 8.01 (1H, d, *J*=4.9 Hz), 8.03–8.16 (1H, br), 8.09–8.12 (2H, m), 8.16 (1H, d, *J*=7.5 Hz), 8.71 (1H, d, *J*=4.9 Hz), 9.59 (1H, bs); ¹³C NMR (CDCl₃) δ : 23.9, 30.2, 60.7, 114.3, 115.9, 121.8, 124.8, 128.5, 129.3, 130.4, 133.1, 134.3, 134.9, 137.1, 138.0, 144.2, 169.5, 172.1. Anal. calcd for C₂₂H₁₇N₃O₄S: C, 63.00; H, 4.09; N, 10.02. Found: C, 62.94; H, 3.74; N, 9.96.

4.5. Asymmetric addition of allyltributyltin to 9-pyroglutamyl- β -carbolines **5** in the presence of 2,2,2-trichloroethyl chloroformate

To the CH₂Cl₂ solution (1 ml) of **5** (0.1 mmol) and allyltributyltin (0.3 mmol) was added 2,2,2-trichloroethyl

chloroformate (0.2 mmol) at –78°C under Ar atmosphere, and the reaction was continued for 24 h at the same temperature. After 3 M aqueous KF solution (10 ml) and CH₂Cl₂ (10 ml) were added, the mixture was stirred vigorously for another 1 h. Then the organic layer was separated, dried over MgSO₄, and evaporated off. The residue was chromatographed on silica gel (CH₂Cl₂–AcOEt) to give the adduct **6** as a colorless oil. The compound **6** was found to be unstable, and its NMR spectra were given as those of a mixture of diastereomers and conformational isomers. Thus, the adduct **6** was subjected to alkaline hydrolysis without further purification. To the THF solution (1 ml) of **6** was added 1 M aqueous NaOH solution (2 ml), and the mixture was allowed to react for 30 min at room temperature. After H₂O was added, the mixture was extracted with CH₂Cl₂, and the organic layer was dried over MgSO₄ and evaporated. A residue thus obtained was confirmed by NMR to be a pure compound **7**.⁶ The aqueous layer was acidified with dil. HCl and extracted with CH₂Cl₂. The organic layer thus obtained was dried over MgSO₄, and evaporated off to leave almost pure compound **4** in a quantitative yield.

4.6. The reaction of 9-pyroglutamyl- β -carboline **5** with silyl enol ethers

2,2,2-Trichloroethyl chloroformate (0.2 mmol) was added to the mixture of compound **5** (0.1 mmol) and a silyl enol ether (0.3 mmol) in CH₂Cl₂ (1 ml) at the temperature shown in Table 4 under Ar, and the mixture was allowed to react for 0.5–40 h until the complete consumption of **5**. After diluted with THF (1 ml), 1 M NaOH (1 ml) was added to the mixture, which was allowed to stir for 1 h at room temperature. Then the mixture was diluted with water and extracted with CH₂Cl₂. The organic layer was dried over MgSO₄, and evaporated off to leave the residue, which was chromatographed on silica gel to give the product **8**. The aqueous layer was acidified with dil. HCl and extracted with CH₂Cl₂. The organic layer thus obtained was dried over MgSO₄, and evaporated off to leave almost pure compound **4** in a quantitative yield.

4.6.1. 1,2-Dihydro-1-(2-oxopropyl)-2-(2,2,2-trichloroethoxycarbonyl)- β -carboline (8a). Yield 40%; Pale yellow powder; mp 145–150°C; $[\alpha]_D^{20} = -219.4$ (*c* 0.22, CHCl₃). The product was obtained as a mixture of two conformational isomers. The ¹H and ¹³C NMR spectra of minor one are shown in parentheses. ¹H NMR (CDCl₃, 60°C) δ : 2.12 (3H, s), 2.97–3.20 (2H, m), 4.73 (4.64) (1H, d, *J*=11.9 Hz), 4.99 (5.13) (1H, d, *J*=11.9 Hz), 6.03 (6.09) (1H, dd, *J*=10.3, 3.0 Hz (9.8, 2.8 Hz)), 6.16 (6.22) (1H, d, *J*=7.7 Hz), 6.69 (6.71) (1H, d, *J*=7.7 Hz), 7.11–7.20 (2H, m), 7.34 (7.33) (1H, d, *J*=7.8 Hz), 7.57 (1H, d, *J*=7.5 Hz), 8.76 (8.68) (1H, s); ¹³C NMR (CDCl₃) δ : 30.3 (30.2), 48.4 (48.8), 48.9 (50.2), 75.5 (75.2), 95.0 (95.1), 104.0, 106.3 (106.4), 111.52 (111.47), 117.1 (118.0), 118.0 (118.2), 120.21 (120.23), 122.17 (122.19), 123.40 (123.44), 130.6 (130.5), 135.78 (135.81), 151.5 (151.3), 208.3 (208.2). Anal. calcd for C₁₇H₁₅C₁₃N₂O₃: C, 50.83; H, 3.76; N, 6.97. Found: C, 50.60; H, 3.42; N, 6.69.

4.6.2. 1,2-Dihydro-1-(2-oxo-2-phenylethyl)-2-(2,2,2-trichloroethoxycarbonyl)- β -carboline (8b). Yield 79%;

colorless needles from hexane–AcOEt; mp 152–155°C; $[\alpha]_D^{20} = -335.0$ (*c* 0.30, CHCl₃); The product was obtained as a mixture of two conformational isomers. The ¹H and ¹³C NMR spectra of minor one are shown in parentheses. ¹H NMR (CDCl₃, 60°C) δ: 3.48 (3.61) (1H, dd, *J*=18.0, 2.7 Hz), 3.65 (3.70) (1H, dd, *J*=18.0, 10.4 Hz), 4.76 (4.67) (1H, d, *J*=11.9 Hz), 4.99 (5.07) (1H, d, *J*=11.9 Hz), 6.21 (6.27) (1H, d, *J*=7.6 Hz), 6.28 (6.33) (1H, dd, *J*=10.4, 2.7 Hz), 6.77 (6.78) (1H, d, *J*=7.6 Hz), 7.10–7.18 (2H, m), 7.36 (7.35) (1H, d, *J*=7.9 Hz), 7.41–7.45 (2H, m), 7.54–7.58 (2H, m), 7.89 (1H, d, *J*=8.2 Hz), 8.91 (8.84) (1H, s); ¹³C NMR (CDCl₃) δ: 43.9 (45.7), 49.4 (49.3), 75.6 (75.3), 95.1 (95.0), 104.3 (104.2), 106.5 (106.6), 111.63 (111.57), 117.3 (118.2), 118.1 (118.3), 120.29 (120.31), 122.26 (122.28), 123.56 (123.60), 127.9 (128.0), 128.7 (128.8), 131.0 (130.9), 133.8 (133.9), 135.95 (135.94), 136.1 (136.00), 151.7 (151.6), 199.60 (199.56). Anal. calcd for C₂₂H₁₇Cl₃N₂O₃: C, 56.98; H, 3.69; N, 6.04. Found: C, 57.28; H, 3.49; N, 5.77.

4.6.3. 1,2-Dihydro-1-(1-methoxycarbonyl-1-methyl-ethyl)-2-(2,2,2-trichloroethoxycarbonyl)-β-carboline (8c). Yield quant; colorless powder; mp 146–148°C; $[\alpha]_D^{25} = +110.52$ (*c* 2.32, CHCl₃); The product was obtained as a mixture of two conformational isomers. The ¹H and ¹³C NMR spectra of minor one are shown in parentheses. ¹H NMR (CDCl₃, 60°C) δ: 1.10 (3H, s), 1.32 (1.40) (3H, s), 3.71 (3H, s), 4.76 (4.82) (1H, d, *J*=11.9 Hz), 5.06 (4.90) (1H, d, *J*=11.9 Hz), 6.24–6.35 (2H, m), 6.78 (1H, d, *J*=7.5 Hz), 7.12–7.20 (2H, m), 7.35 (1H, d, *J*=7.7 Hz), 7.59 (1H, d, *J*=7.7 Hz), 8.53 (8.47) (1H, s); ¹³C NMR (CDCl₃) δ: 19.3 (18.8), 23.1 (23.8), 50.5 (50.4), 32.3, 56.36 (56.43), 75.3 (75.6), 95.0 (94.5), 106.1 (106.8), 108.7 (109.0), 111.2, 117.9 (118.0), 119.4 (120.1), 120.0 (120.6), 121.97 (122.03), 123.2, 128.7 (128.6), 135.6, 153.2 (152.7), 177.7 (178.0). Anal. calcd for C₁₉H₁₉Cl₃N₂O₄: C, 51.20; H, 4.30; N, 6.28. Found: C, 51.33; H, 4.22; N, 6.06.

4.6.4. 1-Benzyloxycarbonylmethyl-1,2-dihydro-2-(2,2,2-trichloroethoxycarbonyl)-β-carboline (8d). Yield 81%; colorless powder; mp 138–142°C; $[\alpha]_D^{20} = -200.7$ (*c* 0.27, CHCl₃); The product was obtained as a mixture of two conformational isomers. The ¹H and ¹³C NMR spectra of minor one are shown in parentheses. ¹H NMR (CDCl₃, 60°C) δ: 2.87–3.04 (2H, m), 4.74 (4.70) (1H, d, *J*=11.9 Hz), 4.98 (5.04) (1H, d, *J*=11.9 Hz), 5.05 (5.03) (1H, d, *J*=12.2 Hz), 5.19 (5.23) (1H, d, *J*=12.2 Hz), 6.05–6.10 (1H, m), 6.17 (6.23) (1H, d, *J*=7.9 Hz), 6.69 (6.70) (1H, d, *J*=7.9 Hz), 7.12–7.20 (2H, m), 7.27–7.31 (3H, m), 7.33–7.36 (3H, m), 7.58 (1H, d, *J*=7.9 Hz), 8.57 (8.54) (1H, s); ¹³C NMR (CDCl₃) δ: 38.6 (40.3), 49.44 (49.46), 67.0 (66.9), 75.6 (75.4), 95.05 (94.96), 104.13 (104.11), 106.87 (106.92), 111.61 (111.57), 117.2, 118.2 (118.3), 120.4, 122.4, 123.5 (123.6), 128.4 (128.3), 128.28 (128.61), 128.7, 130.04 (129.96), 135.1 (135.2), 135.99 (136.03), 151.7 (151.4), 171.7 (171.9). Anal. calcd for C₂₃H₁₉Cl₃N₂O₄: C, 55.95; H, 3.88; N, 5.67. Found: C, 55.83; H, 3.58; N, 5.54.

4.7. Transformation of compound 8d to 10

To the CH₂Cl₂ solution (2 ml) of **8d** (24 mg, 0.049 mmol) and triethylsilane (200 μl, 1.26 mmol) was added

trifluoroacetic acid (100 μl, 1.30 mmol), and the mixture was allowed to react for 15 min. Then the mixture was diluted with CH₂Cl₂, washed with 10% Na₂CO₃, dried over MgSO₄, and evaporated off in vacuo to leave a residue, which was chromatographed on silica gel (CH₂Cl₂) to give compound **9** (21 mg, 0.042 mmol, 87% yield). To the THF (0.35 ml)/H₂O (0.25 ml) solution of compound **9** (20 mg, 0.04 mmol) was added acetic acid (20 μl, 0.35 mmol) and zinc powder (11 mg, 0.17 mmol) successively, and the mixture was allowed to react for 3 h. Then ethyl acetate (15 ml) was added, and the organic layer was washed with 5% Na₂CO₃ (3 ml) and brine (1 ml) respectively, dried over MgSO₄, and evaporated off. The residue was dissolved in MeOH (1 ml), and the solution was treated with sodium methoxide (0.016 mmol) for 2.5 h at room temperature. Then the solution was neutralized with 1N HCl, and the methanol was evaporated off. The aqueous layer thus obtained was basified by the addition of 5% Na₂CO₃, and extracted with CH₂Cl₂ (8 ml×2). The organic layer was dried over MgSO₄, and evaporated off to leave a residue, which was chromatographed on silica gel (AcOEt–EtOH=5:1) to give the product **10** (9.0 mg, 0.037 mmol) in 92% yield.

4.7.1. 1-Benzyloxycarbonylmethyl-1,2,3,4-tetrahydro-2-(2,2,2-trichloroethoxycarbonyl)-β-carboline (9). Colorless needles from hexane; mp 114–115°C; $[\alpha]_D^{20} = +200.7$ (*c* 0.27, CHCl₃); The product was obtained as a mixture of two conformational isomers. The ¹H and ¹³C NMR spectra of minor one are shown in parentheses. ¹H NMR (CDCl₃) δ: 2.79 (1H, dt, *J*=15.9, 4.6 Hz), 2.86–2.95 (1H, m), 3.01 (1H, d, *J*=7.0 Hz), 3.06 (1H, d, *J*=7.0 Hz), 3.18 (3.24) (1H, td, *J*=12.8, 4.6 Hz), 4.55 (1H, td, *J*=12.8, 4.9 Hz), 4.79 (4.63) (1H, d, *J*=11.9 Hz), 4.83 (4.98) (1H, d, *J*=11.9 Hz), 5.18 (5.17) (1H, d, *J*=12.2 Hz), 5.25 (5.29) (1H, d, *J*=12.2 Hz), 5.72 (5.73) (1H, t, *J*=7.0 Hz), 7.08–7.12 (1H, m), 7.16–7.19 (1H, m), 7.27 (1H, d, *J*=8.6 Hz), 7.34–7.39 (5H, m), 7.48 (1H, t, *J*=7.9 Hz), 8.67 (8.63) (1H, s); ¹³C NMR (CDCl₃) δ: 21.6 (21.1), 39.67 (39.2), 39.70 (39.9), 48.0 (47.8), 67.2, 75.2 (75.1), 95.6 (95.5), 108.4 (108.6), 111.2, 118.2 (118.3), 119.5 (119.6), 122.2 (122.3), 126.2, 128.4 (128.5), 128.6 (128.7), 128.8, 131.9 (132.3), 135.2, 135.7 (135.8), 153.4 (153.0), 172.3 (172.6). Anal. calcd for C₂₃H₂₁Cl₃N₂O₄: C, 55.72; H, 4.27; N, 5.65. Found: C, 55.60; H, 3.96; N, 5.48.

4.7.2. 1,2,3,4-Tetrahydro-1-methoxycarbonylmethyl-β-carboline (10). Colorless powder; mp 140–143°C. The NMR spectrum of **10** was identical with that of the reported one.¹³ ¹H NMR (CDCl₃) δ: 2.22–2.31 (1H, m), 2.59 (1H, ddd, *J*=17.6, 6.6, 4.2 Hz), 2.79–2.98 (3H, m), 4.82 (1H, dd, *J*=13.6, 4.0 Hz), 4.98–5.06 (1H, m), 5.27 (1H, d, *J*=17.3 Hz), 5.32 (1H, d, *J*=17.3 Hz), 6.06 (1H, dd, *J*=9.7, 2.9 Hz), 6.53 (1H, ddd, *J*=9.7, 6.6, 2.0 Hz), 6.96–6.99 (1H, m), 7.11–7.17 (3H, m), 7.25–7.32 (3H, m), 7.36–7.38 (1H, m), 7.57–7.61 (1H, m).

4.8. Molecular orbital calculations

The molecular orbital calculations were carried out using the PM3 procedure¹⁴ with the standard parameters, as implemented in the MOPAC2000 program.

References

1. *The Chemistry of Heterocyclic Compounds*; Saxton, J. E., Ed.; Wiley: Chichester, 1994; Part 4, supplement of Vol. 25.
2. (a) Cox, E. D.; Cook, J. M. *Chem. Rev.* **1995**, *95*, 1797. (b) Waldmann, H.; Schmidt, G.; Janzen, M.; Geb, J. *Tetrahedron* **1994**, *50*, 11865. (c) Yamada, H.; Kawate, T.; Matsumizu, M.; Nishida, A.; Nakagawa, M. *J. Org. Chem.* **1998**, *63*, 6348. (d) Kawate, T.; Yamada, H.; Matsumizu, M.; Nishida, A.; Nakagawa, M. *Synlett* **1997**, 761. (e) Kawate, T.; Yamanaka, M.; Nakagawa, M. *Heterocycles* **1999**, *50*, 1033.
3. (a) Martin, S. F.; Clark, C. W.; Corbett, J. W. *J. Org. Chem.* **1995**, *60*, 3236. (b) Martin, S. F.; Chen, K. X.; Eary, C. T. *Org. Lett.* **1999**, *1*, 79. (c) Yamaguchi, R. *Yuki Gosei Kagaku Kyokaiishi* **1991**, *49*, 128.
4. (a) Meyers, A. I. *Tetrahedron* **1992**, *48*, 2589. (b) Meyers, A. I.; Miller, D. B.; White, F. H. *J. Am. Chem. Soc.* **1988**, *110*, 4778. (c) Meyers, A. I.; Highsmith, T. K.; Buonora, P. T. *J. Org. Chem.* **1991**, *56*, 2960.
5. (a) Yamada, K.; Takeda, M.; Iwakuma, T. *J. Chem. Soc., Perkin Trans. 1* **1983**, 265. (b) Polniaszek, R. P.; Kaufman, C. R. *J. Am. Chem. Soc.* **1989**, *111*, 4859. (c) Noyori, R.; Hashiguchi, S. *Acc. Chem. Res.* **1997**, *30*, 97. (d) Uematsu, N.; Fujii, A.; Hashiguchi, S.; Ikariya, T.; Noyori, R. *J. Am. Chem. Soc.* **1996**, *118*, 4916.
6. (a) Itoh, T.; Matsuya, Y.; Enomoto, Y.; Nagata, K.; Miyazaki, M.; Ohsawa, A. *Synlett* **1999**, 1799. (b) Matsuya, Y.; Itoh, T.; Enomoto, Y.; Ohsawa, A. *Heterocycles* **2000**, *53*, 2357. (c) Itoh, T.; Matsuya, Y.; Enomoto, Y.; Ohsawa, A. *Tetrahedron* **2001**, *57*, 7277.
7. A preliminary communication: Itoh, T.; Nagata, K.; Yokoya, M.; Miyazaki, M.; Ikeda, S.; Matsuya, Y.; Enomoto, Y.; Ohsawa, A. *Synlett* **2001**, 1005.
8. For instance, the addition of (*S*)-alanine derivatives to *N*-9 position of β -carboline resulted in the formation of 9-alanyl derivatives in yields below 20% under standard conditions.
9. Najera, C.; Yus, M. *Tetrahedron: Asymmetry* **1999**, *10*, 2245, and references cited therein.
10. (a) Menezes, R. F.; Zazza, C. A.; Sheu, J.; Smith, M. B. *Tetrahedron Lett.* **1989**, *30*, 3295. (b) O'Meara, J. A.; Jung, M.; Durst, T. *Tetrahedron Lett.* **1995**, *36*, 2559. (c) Roth, E.; Altman, J.; Kapon, M.; Ben-Ishai, D. *Tetrahedron* **1995**, *51*, 801. (d) Behr, J.-B.; Defoin, A.; Pires, J.; Streith, J.; Macjo, L.; Zehnder, M. *Tetrahedron* **1996**, *52*, 3283. (e) Ezquerria, J.; Prieto, L.; Avendano, C.; Martos, J. L.; de la Cuesta, E. *Tetrahedron Lett.* **1999**, *40*, 1575.
11. Silyl enol ethers were synthesized according to the reported method, see: Colvin, E. W. *Silicon Reagents in Organic Synthesis*; Academic: San Diego, 1988; pp 99–105, and references cited therein.
12. In the previous reaction which adopted *N*-phenylsulfonyl-prolinyl group as a chiral auxiliary, addition using silyl enol ethers afforded the products in good yields but poor diastereoselectivity (<20%).
13. Tietze, L. F.; Zhou, Y.; Töpken, E. *Eur. J. Org. Chem.* **2000**, 2247.
14. Stewart, J. J. P. *J. Comput. Chem.* **1989**, *10*, 221.
15. The coordination mechanism was supposed to participate only in the reaction of β -carbolines which have two carbonyl and/or sulfonyl oxygens at the reaction sites. In the cases of isoquinoline derivatives, only the steric factor might control the stereochemistry; see (a) Itoh, T.; Nagata, K.; Miyazaki, M.; Ohsawa, A. *Synlett* **1999**, 1154. (b) Itoh, T.; Nagata, K.; Miyazaki, M.; Kameoka, K.; Ohsawa, A. *Tetrahedron* **2001**, *57*, 8827. (c) Nagata, K.; Itoh, T.; Kameoka, K.; Miyazaki, M.; Ohsawa, A. *Heterocycles* **2001**, *55*, 2269.
16. When 3 equiv. of HMPA was added to the reaction shown in entry 6 of Table 3, the ee was lowered to 50%.
17. Enantioselective synthesis of an alkaloid and an alkaloid derivative was carried out using the product described in the present paper, see: Itoh, T.; Miyazaki, M.; Nagata, K.; Yokoya, M.; Nakamura, S.; Ohsawa, A. *Heterocycles* **2002**, *58*, 115.
18. (a) Petersen, J. S.; Fels, G.; Rapoport, H. *J. Am. Chem. Soc.* **1984**, *106*, 4539. (b) Campaigne, E.; Matthews, D. P. *J. Heterocycl. Chem.* **1975**, *12*, 391.